Structured speech input for clinical data collection

2003 ◽  
Author(s):  
M.A. Grasso
Keyword(s):  
Data Collection ◽  
Clinical Data ◽  
Speech Input

Experience of Coding Ambulatory Visits to Outpatient Clinics

1996 ◽  
Vol 26 (3) ◽  
pp. 141-144 ◽  
Author(s):  
K Gibson ◽  
J Ives ◽  
M Wilson ◽  
D Richardson
Keyword(s):  
Data Collection ◽  
Clinical Data ◽  
Discharge Summary ◽  
Tertiary Hospital ◽  
Outpatient Clinics

Clinical data for all current outpatients at a large tertiary hospital has been collected for analysis. Patient diagnoses for selected “key” clinics have been coded to ICD-9-CM standards. Methods to reduce the volume of coding required for such data collection are discussed, and include short-lists of codes, default assignment of diagnoses codes according to the nature of visit, and producing a “discharge” summary for outpatients, similar to that routinely produced for inpatients.

The Early Identification of Beginning Stuttering I

1992 ◽  
Vol 1 (3) ◽  
pp. 43-53 ◽  
Author(s):  
Pearl A. Gordon ◽  
Harold L. Luper
Keyword(s):  
Data Collection ◽  
Young Children ◽  
Clinical Data ◽  
Early Identification ◽  
Future Research ◽  
Speech Language Pathologists ◽  
Companion Article

Speech-language pathologists often struggle with the differentiation of stuttering from normal disfluencies in young children. Differential diagnostic protocols are frequently used to aid clinicians in this complex clinical task. In this article the general format and criteria, clinical data collection procedures, documentation, and relative use of quantification in six protocols are examined and discussed. In a forthcoming companion article, we will discuss problems encountered with the use of differential diagnostic protocols and offer suggestions for future research and the use of these protocols.

scholarly journals Collecting clinical data in primary ciliary dyskinesia- challenges and opportunities

F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 2031 ◽  
Author(s):  
Israel Amirav ◽  
Mary Roduta Roberts ◽  
Huda Mussaffi ◽  
Avigdor Mandelberg ◽  
Yehudah Roth ◽  
...  
Keyword(s):  
Data Collection ◽  
Clinical Research ◽  
Clinical Data ◽  
Primary Ciliary Dyskinesia ◽  
Completion Rates ◽  
End User ◽  
Revision Process ◽  
Data Collection And Analysis ◽  
Challenges And Opportunities ◽  
Ciliary Dyskinesia

Rationale: Primary ciliary dyskinesia (PCD) is under diagnosed and underestimated. Most clinical research has used some form of questionnaires to capture data but none has been critically evaluated particularly with respect to its end-user feasibility and utility. Objective: To critically appraise a clinical data collection questionnaire for PCD used in a large national PCD consortium in order to apply conclusions in future PCD research. Methods: We describe the development, validation and revision process of a clinical questionnaire for PCD and its evaluation during a national clinical PCD study with respect to data collection and analysis, initial completion rates and user feedback. Results: 14 centers participating in the consortium successfully completed the revised version of the questionnaire for 173 patients with various completion rates for various items. While content and internal consistency analysis demonstrated validity, there were methodological deficiencies impacting completion rates and end-user utility. These deficiencies were addressed resulting in a more valid questionnaire. Conclusions: Our experience may be useful for future clinical research in PCD. Based on the feedback collected on the questionnaire through analysis of completion rates, judgmental analysis of the content, and feedback from experts and end users, we suggest a practicable framework for development of similar tools for various future PCD research.

Application of NoSQL Technology to Facilitate Storing and Retrieval of Clinical Data Using IndexedDb in Offline Conditions

2020 ◽  
Vol 17 (9) ◽  
pp. 4012-4015
Author(s):  
B. R. Nagarakshitha ◽  
K. S. Lohith ◽  
K. P. Aarthy ◽  
Arjun Gopkumar ◽  
Uma Satya Ranjan
Keyword(s):  
Data Collection ◽  
Clinical Data ◽  
Web Application ◽  
Data Cleaning ◽  
Web Browsers ◽  
Data Store ◽  
Nosql Database ◽  
End To End

Data collection is a very important aspect of any research, especially while dealing with the collection of clinical data. This paper presents a way to collect and manage clinical data using a web application with offline functionality. The whole application is an end-to-end PWA providing an interface to collect the data, store, and query. The available data is very huge and it is unstructured. To store it, a NoSQL database such as Cassandra is most suitable. The data will mostly be used for an OLAP system for querying the data, cleaning and performing analysis on it. In the process of collection of data, the application has to work under low or no bandwidth conditions for which a NoSQL system provided by most web browsers called IndexedDB, can be used to locally store data under offline conditions.

An Examination of Variables Involved in Tympanometric Assessment of Eustachian Tube Function in Adults

1979 ◽  
Vol 44 (3) ◽  
pp. 388-396 ◽  
Author(s):  
Melinda W. Seifert ◽  
Michael F. Seidemann ◽  
Gregg D. Givens
Keyword(s):  
Data Collection ◽  
Eustachian Tube ◽  
Clinical Data ◽  
Relative Efficiency ◽  
Eustachian Tube Function ◽  
Ventilatory Function ◽  
Experimental Conditions ◽  
Tube Function ◽  
Normal Adults

Eustachian tube function was assessed tympanometrically in a group of normal adults. A pressure-swallow technique of assessing Eustachian tube ventilatory function was administered with positive and negative induced pressures in the range of ± 200 mm to ± 400 mm H 2 O. This study indicated the relative efficiency of measurement of Eustachian tube function under each of the experimental conditions. Recommendations of procedures for further clinical data collection are presented.

scholarly journals Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3154-3154
Author(s):  
Andrew C. Harris ◽  
Rachel Young ◽  
Steven M. Devine ◽  
William J Hogan ◽  
Francis Ayuk ◽  
...  
Keyword(s):  
Data Collection ◽  
Clinical Data ◽  
Research Funding ◽  
Target Organ ◽  
Bloody Stool ◽  
Upper Gi ◽  
Positive Biopsy ◽  
Gi Symptoms ◽  
Research Consortium ◽  
Stool Volume

Abstract Clinical GVHD staging varies between centers and is not agreed upon by independent reviewers (Weisdorf, BBMT 2003). These inconsistencies help explain why promising GVHD treatments from single center studies have not reproduced in multicenter trials. To address this issue, our international GVHD research consortium has developed guidance that has been refined through consensus following case discussions, resulting in uniform and reproducible GVHD clinical symptom reporting. We record all raw target organ symptom data and apply staging based upon this data (Table 1). Only areas of erythema, bullae and desquamation are quantified because other skin changes are not typical of active GVHD rash. Upper GI symptoms must meet thresholds to diagnose GVHD: anorexia with associated weight loss, nausea and/or 2+ vomiting episodes/day lasting 3+ days. For lower GI GVHD we collect stool volumes excluding formed/mostly-formed stools. Unquantified episodes are counted at 200 ml per episode (3 ml/kg for children <50kg) based upon a chart review of 300 patients with post-BMT diarrhea from any cause. Non-GVHD rectal bleeding that results in flecks or streaks of blood in the stool are ignored for staging. We use the highest daily stool output in the 3 days prior to the diagnosis of lower GI GVHD to determine onset stage and, when available, a 3-day average stool volume for subsequent staging to smooth daily variability. We classify biopsy report interpretation into four standardized categories: Positive (unequivocal presence of GVHD), Equivocal (findings suggestive of GVHD, but the pathologist cannot confirm the diagnosis), Non-diagnostic (no abnormalities or subtle findings insufficient to determine etiology), and Non-GVHD etiology (definitive evidence of another diagnosis without concomitant features suggestive of GVHD). We then combine the biopsy interpretation with clinical decision making to assign an overall confidence level to the diagnosis of GVHD in each target organ (Table 2): Confirmed (positive biopsy, regardless of clinician treatment decision), Probable (GVHD diagnosis is sufficiently favored that treatment is given without a positive biopsy), Possible (symptoms present without a positive biopsy; not treated as GVHD), Negative (no symptoms or symptoms are present but a GVHD diagnosis is not entertained and a non-GVHD etiology is identified). Uniform clinical data collection is essential for future GVHD trials and requires application of clear guidance. While still subject to refinement, these guidelines, in use for 2 years by an international research consortium, are designed to be clear, easy to apply, and for clinical trial use. Table 1. GVHD Target Organ Staging Stage Skin (active erythema only) Liver (bilirubin) Upper GI Lower GI (stool output/day) 0 No active (erythematous) GVHD rash < 2 mg/dl No or intermittent nausea, vomiting or anorexia Adult: < 500 ml/day or <3 episodes/day Child: < 10 ml/kg/day or <4 episodes/day 1 Rash < 25% BSA 2-3 mg/dl Persistent nausea, vomiting or anorexia Adult: 500-999 ml/day or 3-4 episodes/day Child: 10 -19.9 ml/kg/day or 4-6 episodes/day 2 Rash 25 - 50% BSA 3.1-6 mg/dl - Adult: 1000-1500 ml/day or 5-7 episodes/day Child: 20 - 30 ml/kg/day or 7-10 episodes/day 3 Rash > 50% BSA 6.1-15 mg/dl - Adult: >1500 ml/day or >7 episodes/day Child: > 30 ml/kg/day or >10 episodes/day 4 Generalized rash (>50% BSA) and bullous formation or desquamation > 5% BSA >15 mg/dl - Severe abdominal pain with or without ileus, or grossly bloody stool (volume independent) Table 2. Confidence Levels Pathologic evidence Clinician assessment Treatment for acute GVHD Comments Confirmed Unequivocal evidence of GVHD GVHD is the etiology for symptoms Not required GVHD is clearly present even if other etiologies co-exist simultaneously Probable Not required (includes equivocal and non-diagnostic biopsies) GVHD most likely etiology for symptoms Yes GVHD is most likely present but other etiologies may also explain the symptoms and there insufficient evidence to make a confirmed diagnosis Possible GVHD in differential diagnosis (but no treatment is being provided) No GVHD may be present, but other etiologies are favored Negative Unequivocal evidence of a diagnosis other than GVHD (e.g., drug rash) GVHD is not considered as an explanation for the symptoms No and the symptoms resolve without GVHD treatment A "negative" biopsy (e.g., normal skin) is not unequivocal evidence of a diagnosis other than GVHD Disclosures Devine: Genzyme: Research Funding. Chen:Bayer: Consultancy, Research Funding. Porter:Novartis: Patents & Royalties, Research Funding. Levine:Novartis: Consultancy.

NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances

2020 ◽  
Vol 36 (4) ◽  
pp. 426-433
Author(s):  
Pilar Pinilla-Dominguez ◽  
Huseyin Naci ◽  
Leeza Osipenko ◽  
Elias Mossialos
Keyword(s):  
Data Collection ◽  
Healthcare System ◽  
Clinical Data ◽  
Risk Mitigation ◽  
Marketing Authorization ◽  
European Medicines Agency ◽  
Substantial Impact ◽  
Early Access ◽  
The Status ◽  
The Impact

ObjectivesTo investigate the impact of the uncertainty stemming from products with European conditional marketing authorization (CMA) or authorization in exceptional circumstances (AEC) on the National Institute for Health and Care Excellence's (NICE) recommendations.MethodsProducts which received CMA/AEC by European Medicines Agency (EMA) up to 1 December 2016 were identified and matched with corresponding NICE decisions issued by August 2017, the status of which was then traced to August 2019. We assessed whether the conversion of CMA to full marketing authorization triggered a review of a NICE decision. The odds of a recommendation carrying a commercial arrangement for products with and without CMA/AEC were calculated.ResultsFifty-four products were granted CMA/AEC by EMA. NICE conducted thirty evaluations of products with CMA/AEC. Twelve products were recommended by NICE by August 2017 and fourteen by August 2019. All recommendations had an associated commercial arrangement. The odds of carrying a commercial arrangement were higher for products with CMA/AEC compared to those with full authorization. Conversions from conditional to full authorization among products not recommended by NICE did not trigger an appraisal review.ConclusionsUncertainty, stemming from the lack of robust clinical data of products authorized with CMA/AEC, has a substantial impact on HTA recommendations, frequently requiring risk mitigation mechanisms such as commercial and data collection arrangements. Further analyses should be conducted to assess whether the benefits of early access strategies outweigh the risks for patients and the healthcare system.

Sign in / Sign up

Export Citation Format

Share Document